Meenakshi Bewtra, MD, PhD, MPH
Associate Professor of Medicine (Gastroenterology) at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
423 Guardian Drive
724 Blockley Hall
Philadelphia, PA 19104
724 Blockley Hall
Philadelphia, PA 19104
Office: 215-746-4922
Publications
Education:
BSc
Yale University, New Haven, CT, 1998.
MD
University of Pennsylvania, Philadelphia, PA, 2003.
MPH
Harvard University School of Public Health, Boston, MA, 2003.
PhD (Epidemiology)
University of Pennsylvania, 2013.
BSc
Yale University, New Haven, CT, 1998.
MD
University of Pennsylvania, Philadelphia, PA, 2003.
MPH
Harvard University School of Public Health, Boston, MA, 2003.
PhD (Epidemiology)
University of Pennsylvania, 2013.
Links
Search PubMed for articles
Penn Medicine Inflammatory Bowel Disease Program
Penn Medicine at Radnor
The IBD-Immunology Initiative (I3) is a prospective biobank enrolling all inflammatory bowel disease patients (IBD) at UPenn. The I3 has collaborators within Penn, nationally and internationally in academia, private foundations and industry.
The Undergraduate Clinical Scholars Program is an epidemiology and biostatistics summer research enrichment program with research mentoring, with a goal of fostering strong research interests and durable mentoring relationships in human clinical research.
I am an active science, research and public health advocate.
University of Pennsylvania Perelman School of Medicine Center for Clinical Epidemiology and Biostatistics (CCEB)
Permanent linkSearch PubMed for articles
Penn Medicine Inflammatory Bowel Disease Program
Penn Medicine at Radnor
The IBD-Immunology Initiative (I3) is a prospective biobank enrolling all inflammatory bowel disease patients (IBD) at UPenn. The I3 has collaborators within Penn, nationally and internationally in academia, private foundations and industry.
The Undergraduate Clinical Scholars Program is an epidemiology and biostatistics summer research enrichment program with research mentoring, with a goal of fostering strong research interests and durable mentoring relationships in human clinical research.
I am an active science, research and public health advocate.
University of Pennsylvania Perelman School of Medicine Center for Clinical Epidemiology and Biostatistics (CCEB)
Selected Publications
Bewtra, Meenakshi; Schreiber, Stefan; Buisson, Anthony; Hur, Peter; Panattoni, Laura; Hauber, Brett; Gahlon, Grace; Coulter, Josh; Smith, Christina; Guo, Xiang; Land, Natalie; Wosik, Karolina; Cappelleri, Joseph; Maravic, Melissa Culhane; Walsh, Alissa : Comparing the benefit-risk tradeoffs advanced therapy naïve vs experienced patients are willing to accept when selecting advanced therapy for moderate-to-severe ulcerative colitis: A discrete choice experiment in the United States and Europe. Digestive Disease Week, San Diego CA May 2025.Regueiro MD, Bewtra M, Dubinsky MC, Branquinho D, Feng C, McDonnell A, Gianfrancesco MA.: Safety Outcomes in Patients With Ulcerative Colitis Using a Healthcare Administrative Database in the United States. Inflamm Bowel Dis Apr 2025.
Kruger AJ, Dormont F, Capit N, Schilsky S, Roberts A, Lin Y, Badalamenti S, Wiekowski M, Bewtra M, Colombel JF.: Biologic Switch Timing and Risk of Infection in Patients With Ulcerative Colitis/Crohn's Disease: A Retrospective Study. Clin Gastroenterol Hepatol Apr 2025.
Yang JC, Janssen EM, Wallace MJ, Sheahan A, Lynch J, Bewtra M, Marko M, Johnson FR, Bozzi LM.: Quantifying Patient Preferences for Risk Tolerance With Novel Dual Biologic Therapies for Inflammatory Bowel Disease. Am J Gastroenterol Mar 2025.
Schreiber, Stefan; Buisson, Anthony; Bewtra, Meenakshi; Hur, Peter; Panattoni, Laura; Hauber, Brett; Land, Natalie; Coulter, Josh; Gahlon, Grace; Guo, Xiang; Smith, Christina C.; Cappelleri, Joseph C.; Wosik, Karolina; Maravic, Melissa Culhane; Walsh, Alissa: Quantifying the benefit-risk trade-offs adult patients and providers are willing to make when considering advanced therapies for moderate to severe Ulcerative Colitis: A discrete choice experiment. European Crohn’s and Colitis Organisation 2025; Berlin Germany February 2025.
Sehgal P, Lewis JD, Pickett-Blakely O, Nandi N, Bewtra M, Lichtenstein GR.: Safety and Clinical Effectiveness of GLP1 Receptor Agonists in Inflammatory Bowel Disease Patients. Clin Gastroenterol Hepatol Jan 2025.
Kastl AJ, Brenner EJ, Weaver KN, Zhang X, Strople JA, Adler J, Dubinsky MC, Bousvaros A, Watkins R, Dai X, Chen W, Cross RK, Higgins PDR, Ungaro RC, Bewtra M, Bellaguarda EA, Farraye FA, Chun KY, Zikry M, Bastidas M, Firestine AM, Craig RG, Boccieri ME, Long MD, Kappelman MD.: Durable Immune Response and Long-term Efficacy of COVID-19 Vaccination in Children With Inflammatory Bowel Disease. Inflamm Bowel Dis Oct 2024.
Motwani KK, Alizadeh M, Abutaleb A, Grossman J, Wellington J, Cross RK; SPARC-IBD investigators.: Correlation Between Serum and Fecal Biomarkers and Patient-Reported Outcomes in Patients with Crohn's Disease and Ulcerative Colitis. Dig Dis Sci June 2024.
Motwani KK, Alizadeh M, Abutaleb A, Grossman J, Wellington J, Cross RK; SPARC-IBD investigators.: Correction to: Correlation Between Plasma and Fecal Biomarkers and Patient‑Reported Outcomes in Patients with Crohn's Disease and Ulcerative Colitis. Dig Dis Sci June 2024.
Karakasheva TA; Martinez CM; Zhou Y; Rhoades JH; Soto GE; Hix OT; Nettleford SK; Roach DM; Laguerta AM; Thadi A; Aleynick D; Pickering OH; Borodyanskaya Y; Fulton M; Uzun Y; Li N; Bewtra M; Kelsen JR; Tan K; Minn AJ; Lengner CJ; Hamilton KE;: Crohn's Disease Epithelial Cells Exhibit Sustained Inflammatory Progenitor Cell States Digestive Disease Week, Washington DC May 2024 Notes: Oral presentation.